Participated · Series E · Aug 2026

LifeMine Therapeutics is developing LIFE-001, a long-acting injectable that directly binds calcineurin to prevent T-cell activation and aims to avoid the multiorgan toxicities associated with existing calcineurin inhibitors. LIFE-001 is in ongoing Phase 1 single- and multiple-ascending-dose studies involving over 120 adults and has not produced clinically meaningful renal, metabolic or cardiovascular safety signals to date. The company plans to use the new financing to fund a planned Phase 2 kidney transplant study and a Phase 1b islet cell transplant study of LIFE-001. Beyond LIFE-001, LifeMine applies a Top-Down Drug Discovery platform that leverages fungal genomic data, human genetics, bioinformatics, machine learning and synthetic biology to identify new mechanisms of action. Financially, the company has raised approximately $558 million to date. The company also strengthened its commercial leadership by appointing Yves Zinggeler as Chief Commercial Officer.

Participated · Series C · Jun 2026

Flare Therapeutics is a clinical-stage biotech headquartered in Cambridge, Mass., that focuses exclusively on drugging transcription factors using an integrated discovery platform to identify ligands to previously undrugged proteins. The company has prioritized FX-111, a first-in-class degrader targeting ARON for prostate cancer, which received IND clearance and is expected to enter clinical development in Q3 2026. FlareTx is also advancing an ARON RIPTAC program through preclinical development to complement FX-111 and expand its ability to address AR-driven prostate cancer. Separately, FX-909, an oral PPARG inhibitor targeting luminal lineage biology in urothelial cancer, is in a Phase 1B dose expansion and the company intends to progress it via an external partnership. The recent $85M Series C provides capital to advance these programs, support working capital and general corporate purposes. The company appointed Anna Protopapas as CEO concurrent with the financing to guide its next phase of clinical and corporate development.

Participated · Series D · Jun 2026

Lycia Therapeutics is a California-based biotech company whose lead programs target disease-driving proteins that circulate in the blood. The company employs a platform the investor describes as able to reach proteins outside the cell, addressing targets conventional drugs cannot. Lycia has progressed through multiple financing rounds, with RTW Biotech participating in its Series B (September 2021), Series C (2024), and the current Series D. The recent Series D financing totals $75M, from which RTW invested $1.4M. Investors and coverage in the reporting frame the use of proceeds around advancing the pipeline toward clinical proof of concept. Financial metrics such as revenue or user counts were not disclosed in the article.

Participated · Series B · Jun 2026

Osanni Bio operates an innovation engine optimized for discovering scientific insights, designing novel drug concepts, and efficiently advancing programs to meaningful proof-of-concept. The platform-centric architecture combines centralized scientific and operational resources with an ecosystem of affiliate companies that receive graduated, de-risked programs and dedicated teams to scale them. Osanni is advancing multiple programs in ophthalmology and cardiology, among other areas. The company is headquartered in San Francisco and is led by a team of inventors and entrepreneurs with repeat company-creation experience. Financially, Osanni just closed a $190 million Series B led by Patient Square Capital to advance its pipeline and scale its discovery and development process.

Participated · Series B · Jun 2026

City Therapeutics is developing a pipeline of RNA interference (RNAi) therapeutics using a next‑generation RNAi engineering platform. The company has initiated a Phase 1 clinical trial of CITY‑FXI targeting Factor XI and reported positive preclinical data for CITY‑RBP4, a candidate for Stargardt disease. It has announced strategic collaborations with Bausch + Lomb and Biogen and plans to advance two programs to clinical stage this year while progressing additional programs toward the clinic by year‑end 2026. City Therapeutics is based in Cambridge, MA, and has raised over $230 million from life sciences investors to date. The recent $99.5 million Series B is intended to accelerate its platform, expand the pipeline, and support business development and partnership activities.